全文获取类型
收费全文 | 34597篇 |
免费 | 2931篇 |
国内免费 | 987篇 |
专业分类
耳鼻咽喉 | 192篇 |
儿科学 | 1096篇 |
妇产科学 | 430篇 |
基础医学 | 5430篇 |
口腔科学 | 606篇 |
临床医学 | 3370篇 |
内科学 | 6027篇 |
皮肤病学 | 489篇 |
神经病学 | 1643篇 |
特种医学 | 746篇 |
外国民族医学 | 4篇 |
外科学 | 2954篇 |
综合类 | 5080篇 |
现状与发展 | 11篇 |
预防医学 | 3027篇 |
眼科学 | 535篇 |
药学 | 2677篇 |
18篇 | |
中国医学 | 1659篇 |
肿瘤学 | 2521篇 |
出版年
2024年 | 71篇 |
2023年 | 850篇 |
2022年 | 1190篇 |
2021年 | 2121篇 |
2020年 | 1669篇 |
2019年 | 1387篇 |
2018年 | 1352篇 |
2017年 | 1342篇 |
2016年 | 1395篇 |
2015年 | 1303篇 |
2014年 | 2217篇 |
2013年 | 2562篇 |
2012年 | 1875篇 |
2011年 | 1981篇 |
2010年 | 1644篇 |
2009年 | 1553篇 |
2008年 | 1477篇 |
2007年 | 1465篇 |
2006年 | 1355篇 |
2005年 | 1161篇 |
2004年 | 983篇 |
2003年 | 801篇 |
2002年 | 759篇 |
2001年 | 671篇 |
2000年 | 589篇 |
1999年 | 518篇 |
1998年 | 438篇 |
1997年 | 381篇 |
1996年 | 381篇 |
1995年 | 340篇 |
1994年 | 327篇 |
1993年 | 243篇 |
1992年 | 224篇 |
1991年 | 244篇 |
1990年 | 165篇 |
1989年 | 158篇 |
1988年 | 170篇 |
1987年 | 170篇 |
1986年 | 132篇 |
1985年 | 163篇 |
1984年 | 152篇 |
1983年 | 90篇 |
1982年 | 132篇 |
1981年 | 62篇 |
1980年 | 63篇 |
1979年 | 54篇 |
1978年 | 35篇 |
1977年 | 27篇 |
1976年 | 25篇 |
1973年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 300 毫秒
11.
12.
目的评估血肌酐和尿常规的常规检测基础上联合血清胱抑素C和尿微量白蛋白检测在人类免疫缺陷病毒(HIV)感染者肾功能损伤检测中的应用价值。
方法以2019年2~5月于首都医科大学附属北京地坛医院感染一科住院的169例HIV感染者为研究对象,完善其尿常规、尿微量白蛋白、血肌酐、血清胱抑素C检测;分析尿蛋白及尿微量白蛋白的阳性检出率及其差异,血肌酐升高及血清胱抑素C升高的比例及其差异。计算应用替诺福韦酯(TDF)及合并丙型肝炎、高血压、糖尿病、肿瘤的肾功能损伤的相对危险度。
结果169例HIV感染者中尿常规示尿蛋白阳性者5例(3.0%),尿微量白蛋白升高者17例(10.1%),两者阳性检出率差异具有统计学意义(χ2 = 5.9、P = 0.007)。血肌酐升高者10例(5.9%),血清胱抑素C升高者20例(11.8%),两者阳性检出率差异具有统计学意义(χ2 = 3.0、P = 0.042)。在尿常规和血肌酐检测的基础上联合检测尿微量白蛋白和血清胱抑素C的总体阳性检出率为49例(30.0%)。CD4+ T淋巴细胞计数< 200个/μl与≥ 200个/μl组患者血清胱抑素C水平分别为0.94(0.83,1.05)mg/L、0.85(0.77,0.95)mg/L,差异具有统计学意义(Z =-3.02、P = 0.003)。应用TDF及合并丙型肝炎、高血压、糖尿病、肿瘤的肾功能损伤的相对危险度分别为1.1、1.5、1.9、2.2和1.4。
结论HIV感染者中,单纯以尿常规为依据评估有无蛋白尿,以血肌酐水平为依据评估肾小球滤过功能会低估肾功能损伤的患病率。在常规检测血肌酐和尿常规的基础上联合检测血清胱抑素C和尿微量白蛋白在提高HIV感染者肾功能损伤检出率方面具有重要的应用价值。低CD4+ T淋巴细胞计数、应用TDF及合并丙型肝炎、高血压、糖尿病、肿瘤均为肾功能损伤的危险因素。 相似文献
13.
14.
The effect of maternal antibodies on the cellular immune response after infant vaccination: A review
《Vaccine》2020,38(1):20-28
During the last few decades, maternal immunization as a strategy to protect young infants from infectious diseases has been increasingly recommended, yet some issues have emerged. Studies have shown that for several vaccines, such as live attenuated, toxoid and conjugated vaccines, high maternal antibody titers inhibit the infant’s humoral immune response after infant vaccination. However, it is not clear whether this decreased antibody titer has any clinical impact on the infant’s protection, as the cellular immune responses are often equally important in providing disease protection and may therefore compensate for diminished antibody levels. Reports describing the effect of maternal antibodies on the cellular immune response after infant vaccination are scarce, probably because such studies are expensive, labor intensive and utilize poorly standardized laboratory techniques. Therefore, this review aims to shed light on what is currently known about the cellular immune responses after infant vaccination in the presence of high (maternal) antibody titers both in animal and human studies. Overall, the findings suggest that maternally derived antibodies do not interfere with the cellular immune responses after infant vaccination. However, more research in humans is clearly needed, as most data originate from animal studies. 相似文献
15.
16.
目的 探讨肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)术前天冬氨酸氨基转移酶与淋巴细胞比值(aspartate aminotransferase to lymphocyte ratio index,ALRI)在原发性肝癌并门脉癌栓(primary liver cancer-portal vein tumor thrombosis,PLC-PVTT)患者预后预测中的价值。方法 选取2013年11月21日至2018年8月22日于广西医科大学附属肿瘤医院接受TACE治疗的175例PLC-PVTT患者为研究对象。采用时间依赖性ROC曲线确定ALRI的最佳临界值。采用Cox 回归模型分析总生存期(overall survival,OS)的独立预测因素,Kaplan-Meier法计算生存率。结果 ROC曲线显示,ALRI的最佳临界值为49.37,对应曲线下面积为0.71。Kaplan-Meier分析显示,ALRI>49.37的患者OS较ALRI≤49.37的患者短(P=0.003)。Cox 回归分析结果显示,ALRI>49.37、行1次以上TACE治疗、Child-Pugh分级B级、凝血酶原时间≥13 s是患者TACE术后OS的独立危险因素(均P<0.05)。结论 TACE术前ALRI>49.37是PLC-PVTT患者OS的独立危险因素。 相似文献
17.
《Research in social & administrative pharmacy》2020,16(1):17-24
BackgroundA number of key publications in recent years have advocated a more integrated vision of UK primary care involving increased multi-professional communication and understanding. This has resulted in a marked change in the roles being undertaken by pharmacists. Community pharmacists have traditionally provided a medicine supply function and treated minor ailments in addition to delivering a suite of locally commissioned services; however these functions have not necessarily been part of a programme of care involving the other clinicians associated with the patient. An integrated model of care would see much closer working between pharmacy and general practice but also with pharmacists not only working with, but in the practice, in an enhanced patient-facing role, trained as independent prescribers. This has implications for the dynamics amongst professionals in this environment.ObjectivesThis exploratory multiple case study attempts to explore these changing dynamics across ten GP surgeries throughout the South-East of England.MethodsSemi-structured, in-depth interviews were conducted with one nurse, one pharmacist and one physician from each clinic, and survey data was collected from 38 patients who had appointments with a pharmacist.ResultsThe data suggested that the pharmacists who had enhanced roles perceived some uncertainty about their professional role and identity, which resulted in instability and insecurity and that this uncertainty led to both professional and interprofessional tension with their primary care colleagues. The survey data revealed that n = 35 (92%) patients stated they were ‘very satisfied’ or ‘satisfied’ with their appointment. And n = 37 (97%) were ‘very comfortable’ or ‘comfortable’ discussing their medications with the pharmacist. In addition, 36 patients (95%) reported that they strongly agreed or agreed with the clinical recommendations made by the pharmacist.ConclusionsThese findings are discussed in relation to role expansion and professional/interprofessional relations before key practical suggestions are offered. 相似文献
18.
Eric S. Zhou Larissa Nekhlyudov Sharon L. Bober 《Translational andrology and urology》2015,4(2):218-231
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples. 相似文献
19.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献
20.